poisar

Stocks · News reference

Johnson & Johnson Announces CAPLYTA Demonstrates Reduction In Signs, Symptoms Of Acute Manic Episodes Associated With Bipolar I Disorder In Phase 3 Trial

Benzinga Newsdesk

Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 study evaluating CAPLYTA® (lumateperone) for the treatment of manic episodes with or without mixed features in adults

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

JNJ
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

    The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

    JNJMLTXABBVAMGNTAK
  3. Dana George

    The Investing Playbook for Retirees Who Can't Afford to Lose

    The article provides a strategic framework for retirees on fixed incomes to protect their savings while managing inflation risk. It recommends a three-bucket approach: maintaining 12-24 months of expenses in cash/short-term fixed income, holding inflation-beating investments with dividend stocks, and allocating remaining funds to long-term growth stocks. The strategy emphasizes identifying essential expenses, calculating guaranteed income gaps, and using bond ladders and high-yield savings accounts to avoid forced asset sales during market downturns.

    JNJMAKO